NCT04613180

Evaluation of the Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis

Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Samarkand State Medical Institute · Academic / Other
• Sex: All
• Age: 1 Year – 7 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study was to evaluate the effectiveness of montelukast sodium in the treatment and prevention of recurrent obstructive bronchitis in children. The investigators examined 80 children aged 1 to 7 years with recurrent obstructive bronchitis, who were randomly divided into 2 groups.

Detailed description

The aim of the study was to evaluate the effectiveness of montelukast sodium in the treatment and prevention of recurrent obstructive bronchitis in children. The investigators examined 80 children aged 1 to 7 years with recurrent obstructive bronchitis, who were randomly divided into 2 groups. Group I (control) included 40 patients who received standard therapy and placebo. Group II (main) included 40 patients who received standart therapy and oral montelukast sodium.

Conditions

• Acute Bronchiolitis

Interventions

Type	Name	Description
DRUG	Montelukast Sodium	Montelukast is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. Montelukast is also used to prevent bronchospasm (breathing difficulties) during exercise in adults and children 6 years of age and older.
DRUG	Placebo	placebo containing no active substance

Timeline

• Start date: 2018-01-03
• Primary completion: 2023-12-30
• Completion: 2024-06-01
• First posted: 2020-11-03
• Last updated: 2020-11-03

Locations

1 site across 1 country: Uzbekistan

Regulatory

• FDA-regulated drug study